ExchangeDEX+
Buy CryptoMarketsSpotFutures500XEarnEvents
More
ETHFI Euphoria
DUBLIN, Dec. 17, 2025 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:DUBLIN, Dec. 17, 2025 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:

Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Author: AI JournalSource: AI Journal
2025/12/18 05:30
MemeCore
M$1.65859-0.78%
PoP Planet
P$0.01755+3.41%

DUBLIN, Dec. 17, 2025 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:

Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026

  • The Company will host an investor webcast on Friday, January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT to review results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. The webcast will include commentary from the Company’s senior management and Dr. Geoffrey Ku, Associate Attending physician on the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. The webcast will take place following the oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026.

44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026

  • The Company will webcast its corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference. Renee Gala, president and chief executive officer, will provide an overview of the company strategy and a business update on Tuesday, January 13, 2026, at 11:15 a.m. PST / 7:15 p.m. GMT.

Audio webcasts of the presentations may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be available on the website for 30 days.  

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com     
Ireland, +353 1 634 3211
U.S., +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland, +353 1 637 2141
U.S., +1 215 867 4948

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-upcoming-investor-events-302645145.html

SOURCE Jazz Pharmaceuticals plc

Market Opportunity
MemeCore Logo
MemeCore Price(M)
$1.65859
$1.65859$1.65859
-1.15%
USD
MemeCore (M) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump to Announce Fed Chair Soon: "Someone Who Believes in Lower Interest Rates by a Lot"

Trump to Announce Fed Chair Soon: "Someone Who Believes in Lower Interest Rates by a Lot"

US President Donald Trump has revealed plans to soon name the next Federal Reserve chairman, emphasizing a candidate who "believes in lower interest rates by a lot." This statement signals a potential shift toward more accommodative monetary policy, which could have significant implications for financial markets, including cryptocurrencies.
Share
MEXC NEWS2025/12/18 17:43
XRP Price Falls Below $2, Deepening Investor Concerns

XRP Price Falls Below $2, Deepening Investor Concerns

XRP closed below $2, raising concerns about a deeper pullback. Technical indicators and moving averages support a bearish outlook for XRP. Continue Reading:XRP
Share
Coinstats2025/12/18 16:10
BlackRock Increases U.S. Stock Exposure Amid AI Surge

BlackRock Increases U.S. Stock Exposure Amid AI Surge

The post BlackRock Increases U.S. Stock Exposure Amid AI Surge appeared on BitcoinEthereumNews.com. Key Points: BlackRock significantly increased U.S. stock exposure. AI sector driven gains boost S&P 500 to historic highs. Shift may set a precedent for other major asset managers. BlackRock, the largest asset manager, significantly increased U.S. stock and AI sector exposure, adjusting its $185 billion investment portfolios, according to a recent investment outlook report.. This strategic shift signals strong confidence in U.S. market growth, driven by AI and anticipated Federal Reserve moves, influencing significant fund flows into BlackRock’s ETFs. The reallocation increases U.S. stocks by 2% while reducing holdings in international developed markets. BlackRock’s move reflects confidence in the U.S. stock market’s trajectory, driven by robust earnings and the anticipation of Federal Reserve rate cuts. As a result, billions of dollars have flowed into BlackRock’s ETFs following the portfolio adjustment. “Our increased allocation to U.S. stocks, particularly in the AI sector, is a testament to our confidence in the growth potential of these technologies.” — Larry Fink, CEO, BlackRock The financial markets have responded favorably to this adjustment. The S&P 500 Index recently reached a historic high this year, supported by AI-driven investment enthusiasm. BlackRock’s decision aligns with widespread market speculation on the Federal Reserve’s next moves, further amplifying investor interest and confidence. AI Surge Propels S&P 500 to Historic Highs At no other time in history has the S&P 500 seen such dramatic gains driven by a single sector as the recent surge spurred by AI investments in 2023. Experts suggest that the strategic increase in U.S. stock exposure by BlackRock may set a precedent for other major asset managers. Historically, shifts of this magnitude have influenced broader market behaviors as others follow suit. Market analysts point to the favorable economic environment and technological advancements that are propelling the AI sector’s momentum. The continued growth of AI technologies is…
Share
BitcoinEthereumNews2025/09/18 02:49